Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · May 10, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 2 diabetes ;
• • Proteinuria ≥ 0.5 g / g motivating the prescription of ACE inhibitors or ARA2 full dose;
• • Processing statin;
• • Processing metformin;
• • court treatment with GLP-1 agonists and DPP-4 inhibitor;
• • About who signed the informed consent;
• • affiliated to the social security issue
• Exclusion Criteria:
• • Diabetic nephropathy not;
• • GFR \<30 ml / min / 1.73 m2;
• • Type 1 diabetes;
• • Maturity Onset Diabetes of the Youth (MODY);
• • Use of telmisartan in the 6 months prior to enrollment;
• • Liver cirrhosis (potential production of PIIINP);
• • chronic inflammatory disease;
• • active cancer;
• • immunosuppression;
• • Pregnant or breastfeeding women (urine pregnancy test will be performed for women of childbearing age);
• • adult person under guardianship;
• • Hospitalized person without his consent and not protected by law; person deprived of liberty